Compounding Pharmacies Market Growth and Industry Forecast
- The global compounding pharmacies market is projected to be valued at US$ 10 Bn in 2025.
- It is expected to expand to US$ 13.9 Bn by 2032, growing at a CAGR of 4.8% between 2025 and 2032.
Compounding Pharmacies Market Summary Key Insights & Trends
- Oral dosage forms lead the market with over 40% share in 2025, driven by pain management and BHRT demand.
- Parenteral formulations are the fastest growing segment, expanding at nearly 6% CAGR due to rising hospital sterile needs.
- Adult patients dominate with 45% share, supported by chronic disease treatments in dermatology and gastroenterology.
- The geriatric group is the fastest growing, projected at 5.5% CAGR with aging populations driving demand.
- Rising personalized medicine needs fuel adoption, with 70% of physicians prescribing compounded drugs globally.
- Emerging markets such as Asia Pacific grow rapidly, with India facing 30% drug shortages supporting compounding uptake.
- North America leads with 45% share, driven by over 300 annual drug shortages and AI-driven sterile compounding.
- Europe and Asia Pacific advance steadily, supported by EU regulations, NHS initiatives, and rising disposable incomes.
A Look Back and a Look Forward - Comparative Analysis
From 2019 to 2024, the Compounding Pharmacies Market demonstrated resilience amid fluctuating dynamics, steadily expanding despite disruptions. The COVID-19 pandemic had a profound impact during this period, initially causing supply chain interruptions and regulatory hurdles that led to temporary closures and reduced operations in early 2020. However, it also spurred growth through heightened demand for compounded medications to address critical drug shortages, particularly in sterile compounding for hospital use. At the same time, non-sterile compounded products gained traction in home care, supported by the surge in telemedicine, though safety concerns and recalls tempered momentum. The market adapted by embracing stricter compliance standards and integrating digital tools for inventory management.
Looking ahead to the forecast period of 2025 to 2032, the industry is expected to accelerate its growth trajectory, driven by technological advancements such as automation and AI in formulation processes that enhance precision and minimize errors. Emerging markets in Asia Pacific will play a significant role through the development of healthcare infrastructure, while global trends toward personalized medicine and veterinary applications are set to foster further innovation. Proactive quality assurance measures and strategic partnerships will help mitigate regulatory challenges, positioning the compounding pharmacies for sustainable expansion amid the growing burden of chronic diseases.
Key Growth Drivers
- Rising Demand for Personalized Medicine Fuels Compounding Pharmacies Growth Worldwide
The compounding pharmacies market is significantly driven by the increasing need for personalized medications, as standard pharmaceutical products often fail to meet specific patient requirements, such as unique dosages or allergen-free formulations. According to industry reports, over 70% of physicians prescribe compounded drugs for patients with special needs, with the global personalized medicine market projected to grow at 10% annually, directly benefiting the market. This driver is justified by the surge in chronic conditions such as diabetes and cancer, where customized therapies improve adherence and outcomes; for instance, in the U.S., drug shortages reported by the FDA reached over 200 in 2024, prompting reliance on compounding pharmacies to fill gaps, thereby expanding market reach. Furthermore, advancements in pharmacogenomics enable precise tailoring, reducing adverse reactions by up to 30%, as per clinical studies, solidifying this as a core growth factor in the compounding pharmacies.
- Drug Shortages and Supply Chain Disruptions Strengthen Role of Compounding Pharmacies
Persistent drug shortages worldwide drive as pharmacies step in to produce essential medications unavailable from manufacturers. The American Society of Health-System Pharmacists reported over 300 shortages in 2024 alone, a 20% increase from pre-COVID levels, justifying the need for compounding to ensure continuity in treatments such as parenteral nutrition. This factor is amplified by geopolitical tensions and manufacturing halts, where compounding pharmacies mitigate risks by providing rapid, localized solutions, boosting market value by an estimated US$ 2 Bn annually. Quality statistics highlight that compounded drugs resolved 40% of U.S. hospital shortages in recent years, enhancing trust and adoption, while regulatory frameworks such as the FDA's outsourcing facilities support safe scaling, positioning this as a resilient driver for the Compounding Pharmacies.
- Aging Population and Chronic Diseases Drive Demand for Compounded Medications
An aging global population is a key driver propelling the industry, with the World Health Organization estimating that by 2032, one in six people will be over 50, increasing demand for geriatric-specific compounded drugs such as adjusted hormone therapies. Statistics show that chronic diseases affect 40% of adults in developed nations, necessitating customized pain management and dermatological solutions, where compounding pharmacies excel by offering flexible dosages that enhance patient compliance by 25-40%. Justification lies in demographic shifts; for example, in Europe, geriatric care expenditures rose 15% from 2019-2024, fueling compounding pharmacies market growth through specialized formulations that address polypharmacy issues. This driver is further reinforced by veterinary applications, as rising pet ownership fuels demand for compounded animal medications.
Key Growth Restraints
- Stringent Regulatory Compliance and Safety Concerns Limit Compounding Pharmacies Expansion
The Compounding Pharmacies Market faces significant restraints from rigorous regulatory requirements, such as the FDA's cGMP standards for sterile compounding, which increase operational costs by 20-30% and lead to frequent inspections or recalls. Safety issues, exemplified by past contamination incidents such as the 2012 fungal meningitis outbreak linked to compounded drugs, erode consumer confidence and result in lawsuits, with over 50 recalls in 2024 alone impacting market growth. Justification includes the high barrier to entry for small pharmacies, limiting expansion and innovation in the compounding pharmacies amid heightened scrutiny post-COVID.
- High Operational Costs and Limited Reimbursement Challenge Compounding Pharmacies Growth
Elevated costs for specialized equipment and trained personnel restrain with sterile facilities requiring investments up to US$ 1 Mn, deterring new entrants and squeezing margins by 15%. Limited insurance reimbursement for compounded drugs, covering only 40-50% of cases in the U.S., discourages patient uptake and pharmacy viability, as per industry analyses. This restraint is justified by economic pressures from inflation and supply chain volatility, which raised raw material costs 10-20% in 2024.
Compounding Pharmacies Market Trends and Opportunities
- Expansion into Emerging Markets Creates Growth Path for Compounding Pharmacies Worldwide
The Compounding Pharmacies Market has substantial opportunities in emerging regions such as Asia Pacific and Latin America, where improving healthcare infrastructure and rising middle-class populations drive demand for affordable customized drugs. Justification includes untapped potential in countries such as India, where drug shortages affect 30% of supplies, allowing compounded solutions to fill voids in pediatric and veterinary care, fostering innovation and market penetration.
- Technological Advancements and Automation Unlock New Potential in Compounding Pharmacies
Advancements in automation and AI present key opportunities for the compounding pharmacies market, enabling precise formulation and reducing errors by 50%, as per recent studies on robotic compounding systems. Investments in digital tools such as inventory management software can streamline operations, cutting costs by 25% and enhancing scalability for high-volume sterile production. This opportunity is justified by the post-COVID emphasis on efficiency, with the global pharmacy automation market reaching US$ 5 Bn in 2024, positioning compounding pharmacies to innovate in areas such as telemedicine-integrated services and expand their role in personalized healthcare.
Segment-wise Trends & Analysis
- Oral Dosage Forms Lead While Parenteral Emerge as Fastest Growing Segment
The oral dosage form segment leads with over 40% market share, driven by its convenience for chronic disease management and ease of customization for patients avoiding allergens or needing specific strengths. Oral compounds, such as capsules and liquids, dominate due to high demand in pain management and hormone therapy, supported by non-sterile processes that lower costs. However, the parenteral segment is the fastest growing fuelled by hospital needs for injectable sterile drugs amid shortages, with advancements in aseptic techniques enhancing safety and adoption. This growth in the compounding pharmacies reflects shifts toward intravenous therapies for critical care, where parenteral dosage form address 30% of U.S. drug shortages, while topical and rectal forms grow steadily for dermatology and gastroenterology applications, and others such as otic preparations fill niche gaps.
- Adult Patient Group Leads as Geriatric Segment Becomes Fastest Growing Category
The adult patient group leads, capturing 45% share, as it encompasses a broad range of chronic conditions requiring customized dosages for compliance and efficacy. Adults benefit from compounded medications in hormone replacement and pain relief, with rising obesity and lifestyle diseases boosting demand. Conversely, the geriatric segment is fastest growing, propelled by an aging population projected to double by 2050, necessitating adjusted formulations to combat polypharmacy and swallowing difficulties. In the compounding pharmacies market, pediatric applications grow through flavored compounds improving adherence, while veterinary use expands with pet humanization trends, contributing to overall segment diversification.
- Pain Management Dominates While Hormone Replacement Therapy Shows Rapidest Growth
Pain management leads the compounding pharmacies market with 35% share, driven by the opioid crisis and need for non-addictive alternatives such as topical creams, addressing chronic pain affecting 20% of adults globally. This dominance is justified by customizable strengths reducing side effects. The hormone replacement therapy (BHRT) segment is fastest growing at 7% CAGR, spurred by menopause treatments and bioidentical hormones, with women's health initiatives amplifying demand. In the market, dermatology and gastroenterology segments grow through specialized topicals and rectals, while others, such as oncology compounding, emerge amid drug shortages.
- Non-Sterile Compounding Leads While Sterile Compounding Becomes Fastest Expanding Segment
Non-sterile compounding leads the compounding pharmacies market, holding 60% share, due to its applicability in oral and topical forms for outpatient care, offering cost-effectiveness and rapid production. This segment thrives on demand for customized creams and capsules. The sterile segment, however, is fastest growing at 6.2% CAGR, driven by hospital requirements for injectables and regulatory emphasis on safety post-recalls. In the industry, sterile growth is fueled by advancements in cleanroom tech, addressing parenteral needs and expanding into veterinary and pediatric applications for enhanced precision.
Regional Analysis
- North America Leads with Strong U.S. Growth and Innovation Trends
North America dominates the market with a 45% share, led by the U.S., where the market is valued at US$ 5.5 Bn in 2025, driven by drug shortages exceeding 300 annually and a focus on personalized medicine. U.S. trends include rising adoption of sterile compounding for hospital use, spurred by FDA outsourcing facilities, and integration of AI for formulation accuracy. Key drivers encompass an aging population and chronic disease prevalence, with telemedicine boosting non-sterile demand. Regulatory reforms post-2024 enhance safety, while expansions by players such as Fresenius Kabi support growth in the compounding pharmacies market.
- Europe Advances Through Robust Healthcare Systems and Supportive Regulations
Europe holds 25% of the compounding pharmacies industry, with Germany and the UK as leading countries, driven by advanced healthcare systems and EU regulations promoting quality compounding. Germany's market grows through geriatric care demands, with hormone therapy compounding rising 8% amid aging demographics. The UK benefits from NHS partnerships addressing shortages, fueled by post-Brexit supply chain resilience. Drivers include chronic disease management and veterinary expansions, positioning Europe for steady advancement.
- Asia Pacific Emerges as Fastest Growing Region with Rising Demand
Asia Pacific is the fastest-growing region, led by China, India, and Japan, where expanding healthcare infrastructure and population growth drive demand. China's market surges with government investments in personalized medicine, addressing urban chronic diseases. India's low-cost compounding thrives on generic shortages, while Japan's aging society boosts geriatric formulations. Key drivers include rising disposable incomes and regulatory harmonization, enhancing accessibility in the compounding pharmacies market.
Competitive Landscape
The compounding pharmacies market is fragmented, with key players focusing on product innovation, strategic partnerships, and geographic expansion to enhance market share. Companies increasingly invest in automation for efficiency, while ensuring strict regulatory compliance to build trust, and mergers help scale sterile compounding operations. Walgreens Co. leverages its extensive retail network for personalized offerings, while Fagron drives global innovation in customized medicine. B. Braun and Fresenius Kabi strengthen sterile compounding capabilities, whereas Clinigen Group, Wedgewood Pharmacy, and Avella Specialty Pharmacy serve niche therapeutic areas. Regional players such as Triangle, Pencol, and US Compounding improve accessibility, while Nephron, Empower, Formul8, and Fusion Apothecary advance automation and compliance.
Key Companies:
- Walgreens Co.
- Fagron
- B. Braun
- Fresenius Kabi
- Clinigen Group
- Wedgewood Pharmacy
- Avella Specialty Pharmacy
- Triangle Compounding Pharmacy
- Pencol Compounding Pharmacy
- US Compounding Inc.
- Central Admixture Pharmacy Services, Inc.
- Nephron Pharmaceuticals Corporation
- Empower Pharmacy
- Formul8
- Fusion Apothecary
Expert Opinion
- September 2025, Pete Pharma partnered with FABRX, the global pioneer of pharmaceutical 3D printing, to introduce this innovative technology to the U.S. compounding pharmacy market. The collaboration between Pete Pharma and FABRX positions both companies as pioneers in compounding innovation, paving the way for pharmacies to enhance operational efficiency while delivering more personalized and effective therapies to patients.
- In January 2025, The U.S. Food and Drug Administration (FDA) has released final interim guidance on compounding with bulk drug substances, reflecting the Agency’s continued efforts to balance patient access to essential compounded medications with the imperative to ensure their safety and efficacy
- In January 2025, Fagron acquired CareFirst Specialty Pharmacy, a U.S.-based non-sterile compounding pharmacy focused on hormone replacement therapy and dermatology, expanding its presence in the North American prevention and lifestyle markets.
Global Compounding Pharmacies Market Segmentation
By Dosage Form:
- Oral
- Topical
- Parenteral
- Rectal
- Others
By Patient Group:
- Pediatric
- Geriatric
- Adult
- Veterinary
By Therapeutic Area:
- Pain management
- Hormone replacement therapy (BHRT)
- Dermatology
- Gastroenterology
- Others
By Sterility:
- Sterile
- Non-Sterile
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
1. Executive Summary
1.1. Global Compounding Pharmacies Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2025
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. COVID-19 Impact Analysis
2.5. Porter's Fiver Forces Analysis
2.6. Impact of Russia-Ukraine Conflict
2.7. PESTLE Analysis
2.8. Regulatory Analysis
2.9. Price Trend Analysis
2.9.1. Current Prices and Future Projections, 2024-2032
2.9.2. Price Impact Factors
3. Global Compounding Pharmacies Market Outlook, 2019 - 2032
3.1. Global Compounding Pharmacies Market Outlook, by Dosage Form, Value (US$ Bn), 2019-2032
3.1.1. Oral
3.1.2. Topical
3.1.3. Parenteral
3.1.4. Rectal
3.1.5. Others
3.2. Global Compounding Pharmacies Market Outlook, by Patient Group, Value (US$ Bn), 2019-2032
3.2.1. Pediatric
3.2.2. Geriatric
3.2.3. Adult
3.2.4. Veterinary
3.3. Global Compounding Pharmacies Market Outlook, by Therapeutic Area, Value (US$ Bn), 2019-2032
3.3.1. Pain management
3.3.2. Hormone replacement therapy (BHRT)
3.3.3. Dermatology
3.3.4. Gastroenterology
3.3.5. Others
3.4. Global Compounding Pharmacies Market Outlook, by Sterility, Value (US$ Bn), 2019-2032
3.4.1. Sterile
3.4.2. Non-Sterile
3.5. Global Compounding Pharmacies Market Outlook, by Region, Value (US$ Bn), 2019-2032
3.5.1. North America
3.5.2. Europe
3.5.3. Asia Pacific
3.5.4. Latin America
3.5.5. Middle East & Africa
4. North America Compounding Pharmacies Market Outlook, 2019 - 2032
4.1. North America Compounding Pharmacies Market Outlook, by Dosage Form, Value (US$ Bn), 2019-2032
4.1.1. Oral
4.1.2. Topical
4.1.3. Parenteral
4.1.4. Rectal
4.1.5. Others
4.2. North America Compounding Pharmacies Market Outlook, by Patient Group, Value (US$ Bn), 2019-2032
4.2.1. Pediatric
4.2.2. Geriatric
4.2.3. Adult
4.2.4. Veterinary
4.3. North America Compounding Pharmacies Market Outlook, by Therapeutic Area, Value (US$ Bn), 2019-2032
4.3.1. Pain management
4.3.2. Hormone replacement therapy (BHRT)
4.3.3. Dermatology
4.3.4. Gastroenterology
4.3.5. Others
4.4. North America Compounding Pharmacies Market Outlook, by Sterility, Value (US$ Bn), 2019-2032
4.4.1. Sterile
4.4.2. Non-Sterile
4.5. North America Compounding Pharmacies Market Outlook, by Country, Value (US$ Bn), 2019-2032
4.5.1. U.S. Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
4.5.2. U.S. Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
4.5.3. U.S. Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
4.5.4. U.S. Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
4.5.5. Canada Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
4.5.6. Canada Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
4.5.7. Canada Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
4.5.8. Canada Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
4.6. BPS Analysis/Market Attractiveness Analysis
5. Europe Compounding Pharmacies Market Outlook, 2019 - 2032
5.1. Europe Compounding Pharmacies Market Outlook, by Dosage Form, Value (US$ Bn), 2019-2032
5.1.1. Oral
5.1.2. Topical
5.1.3. Parenteral
5.1.4. Rectal
5.1.5. Others
5.2. Europe Compounding Pharmacies Market Outlook, by Patient Group, Value (US$ Bn), 2019-2032
5.2.1. Pediatric
5.2.2. Geriatric
5.2.3. Adult
5.2.4. Veterinary
5.3. Europe Compounding Pharmacies Market Outlook, by Therapeutic Area, Value (US$ Bn), 2019-2032
5.3.1. Pain management
5.3.2. Hormone replacement therapy (BHRT)
5.3.3. Dermatology
5.3.4. Gastroenterology
5.3.5. Others
5.4. Europe Compounding Pharmacies Market Outlook, by Sterility, Value (US$ Bn), 2019-2032
5.4.1. Sterile
5.4.2. Non-Sterile
5.5. Europe Compounding Pharmacies Market Outlook, by Country, Value (US$ Bn), 2019-2032
5.5.1. Germany Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
5.5.2. Germany Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
5.5.3. Germany Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
5.5.4. Germany Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
5.5.5. Italy Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
5.5.6. Italy Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
5.5.7. Italy Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
5.5.8. Italy Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
5.5.9. France Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
5.5.10. France Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
5.5.11. France Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
5.5.12. France Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
5.5.13. U.K. Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
5.5.14. U.K. Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
5.5.15. U.K. Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
5.5.16. U.K. Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
5.5.17. Spain Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
5.5.18. Spain Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
5.5.19. Spain Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
5.5.20. Spain Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
5.5.21. Russia Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
5.5.22. Russia Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
5.5.23. Russia Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
5.5.24. Russia Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
5.5.25. Rest of Europe Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
5.5.26. Rest of Europe Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
5.5.27. Rest of Europe Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
5.5.28. Rest of Europe Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
5.6. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Compounding Pharmacies Market Outlook, 2019 - 2032
6.1. Asia Pacific Compounding Pharmacies Market Outlook, by Dosage Form, Value (US$ Bn), 2019-2032
6.1.1. Oral
6.1.2. Topical
6.1.3. Parenteral
6.1.4. Rectal
6.1.5. Others
6.2. Asia Pacific Compounding Pharmacies Market Outlook, by Patient Group, Value (US$ Bn), 2019-2032
6.2.1. Pediatric
6.2.2. Geriatric
6.2.3. Adult
6.2.4. Veterinary
6.3. Asia Pacific Compounding Pharmacies Market Outlook, by Therapeutic Area, Value (US$ Bn), 2019-2032
6.3.1. Pain management
6.3.2. Hormone replacement therapy (BHRT)
6.3.3. Dermatology
6.3.4. Gastroenterology
6.3.5. Others
6.4. Asia Pacific Compounding Pharmacies Market Outlook, by Sterility, Value (US$ Bn), 2019-2032
6.4.1. Sterile
6.4.2. Non-Sterile
6.5. Asia Pacific Compounding Pharmacies Market Outlook, by Country, Value (US$ Bn), 2019-2032
6.5.1. China Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
6.5.2. China Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
6.5.3. China Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
6.5.4. China Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
6.5.5. Japan Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
6.5.6. Japan Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
6.5.7. Japan Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
6.5.8. Japan Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
6.5.9. South Korea Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
6.5.10. South Korea Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
6.5.11. South Korea Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
6.5.12. South Korea Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
6.5.13. India Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
6.5.14. India Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
6.5.15. India Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
6.5.16. India Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
6.5.17. Southeast Asia Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
6.5.18. Southeast Asia Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
6.5.19. Southeast Asia Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
6.5.20. Southeast Asia Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
6.5.21. Rest of SAO Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
6.5.22. Rest of SAO Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
6.5.23. Rest of SAO Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
6.5.24. Rest of SAO Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
6.6. BPS Analysis/Market Attractiveness Analysis
7. Latin America Compounding Pharmacies Market Outlook, 2019 - 2032
7.1. Latin America Compounding Pharmacies Market Outlook, by Dosage Form, Value (US$ Bn), 2019-2032
7.1.1. Oral
7.1.2. Topical
7.1.3. Parenteral
7.1.4. Rectal
7.1.5. Others
7.2. Latin America Compounding Pharmacies Market Outlook, by Patient Group, Value (US$ Bn), 2019-2032
7.2.1. Pediatric
7.2.2. Geriatric
7.2.3. Adult
7.2.4. Veterinary
7.3. Latin America Compounding Pharmacies Market Outlook, by Therapeutic Area, Value (US$ Bn), 2019-2032
7.3.1. Pain management
7.3.2. Hormone replacement therapy (BHRT)
7.3.3. Dermatology
7.3.4. Gastroenterology
7.3.5. Others
7.4. Latin America Compounding Pharmacies Market Outlook, by Sterility, Value (US$ Bn), 2019-2032
7.4.1. Sterile
7.4.2. Non-Sterile
7.5. Latin America Compounding Pharmacies Market Outlook, by Country, Value (US$ Bn), 2019-2032
7.5.1. Brazil Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
7.5.2. Brazil Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
7.5.3. Brazil Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
7.5.4. Brazil Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
7.5.5. Mexico Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
7.5.6. Mexico Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
7.5.7. Mexico Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
7.5.8. Mexico Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
7.5.9. Argentina Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
7.5.10. Argentina Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
7.5.11. Argentina Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
7.5.12. Argentina Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
7.5.13. Rest of LATAM Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
7.5.14. Rest of LATAM Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
7.5.15. Rest of LATAM Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
7.5.16. Rest of LATAM Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
7.6. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Compounding Pharmacies Market Outlook, 2019 - 2032
8.1. Middle East & Africa Compounding Pharmacies Market Outlook, by Dosage Form, Value (US$ Bn), 2019-2032
8.1.1. Oral
8.1.2. Topical
8.1.3. Parenteral
8.1.4. Rectal
8.1.5. Others
8.2. Middle East & Africa Compounding Pharmacies Market Outlook, by Patient Group, Value (US$ Bn), 2019-2032
8.2.1. Pediatric
8.2.2. Geriatric
8.2.3. Adult
8.2.4. Veterinary
8.3. Middle East & Africa Compounding Pharmacies Market Outlook, by Therapeutic Area, Value (US$ Bn), 2019-2032
8.3.1. Pain management
8.3.2. Hormone replacement therapy (BHRT)
8.3.3. Dermatology
8.3.4. Gastroenterology
8.3.5. Others
8.4. Middle East & Africa Compounding Pharmacies Market Outlook, by Sterility, Value (US$ Bn), 2019-2032
8.4.1. Sterile
8.4.2. Non-Sterile
8.5. Middle East & Africa Compounding Pharmacies Market Outlook, by Country, Value (US$ Bn), 2019-2032
8.5.1. GCC Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
8.5.2. GCC Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
8.5.3. GCC Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
8.5.4. GCC Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
8.5.5. South Africa Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
8.5.6. South Africa Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
8.5.7. South Africa Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
8.5.8. South Africa Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
8.5.9. Egypt Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
8.5.10. Egypt Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
8.5.11. Egypt Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
8.5.12. Egypt Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
8.5.13. Nigeria Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
8.5.14. Nigeria Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
8.5.15. Nigeria Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
8.5.16. Nigeria Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
8.5.17. Rest of Middle East Compounding Pharmacies Market Outlook, by Dosage Form, 2019-2032
8.5.18. Rest of Middle East Compounding Pharmacies Market Outlook, by Patient Group, 2019-2032
8.5.19. Rest of Middle East Compounding Pharmacies Market Outlook, by Therapeutic Area, 2019-2032
8.5.20. Rest of Middle East Compounding Pharmacies Market Outlook, by Sterility, 2019-2032
8.6. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Company Vs Segment Heatmap
9.2. Company Market Share Analysis, 2024
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Walgreens Co.
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Developments
9.4.2. Fagron
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Developments
9.4.3. B. Braun
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Developments
9.4.4. Fresenius Kabi
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Developments
9.4.5. Clinigen Group
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Developments
9.4.6. Wedgewood Pharmacy
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Developments
9.4.7. Avella Specialty Pharmacy
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Developments
9.4.8. Triangle Compounding Pharmacy
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Financial Overview
9.4.8.4. Business Strategies and Developments
9.4.9. Pencol Compounding Pharmacy
9.4.9.1. Company Overview
9.4.9.2. Product Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Developments
9.4.10. US Compounding Inc.
9.4.10.1. Company Overview
9.4.10.2. Product Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Developments
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations
|
BASE YEAR |
HISTORICAL DATA |
FORECAST PERIOD |
UNITS |
|||
 |
2024 |
 |
2019 - 2024 |
 |
2025 - 2032 |
Value: US$ Billion |
|
REPORT FEATURES |
DETAILS |
|
Dosage Form Coverage |
|
|
Patient Group Coverage |
|
|
Therapeutic Area Coverage |
|
|
Sterility Coverage |
|
|
Geographical Coverage |
|
|
Leading Companies |
|
|
Report Highlights |
Key Market Indicators, Macro-micro economic impact analysis, Technological Roadmap, Key Trends, Driver, Restraints, and Future Opportunities & Revenue Pockets, Porter’s 5 Forces Analysis, Historical Trend (2019-2024), Market Estimates and Forecast, Market Dynamics, Industry Trends, Competition Landscape, Category, Region, Country-wise Trends & Analysis, COVID-19 Impact Analysis (Demand and Supply Chain) |
Quality assured
